Dianthus Therapeutics Statistics
Total Valuation
DNTH has a market cap or net worth of $1.45 billion. The enterprise value is $1.14 billion.
Important Dates
The next estimated earnings date is Thursday, November 6, 2025, after market close.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DNTH has 38.68 million shares outstanding. The number of shares has increased by 71.34% in one year.
| Current Share Class | 38.68M |
| Shares Outstanding | 38.68M |
| Shares Change (YoY) | +71.34% |
| Shares Change (QoQ) | +0.09% |
| Owned by Insiders (%) | 0.17% |
| Owned by Institutions (%) | 55.99% |
| Float | 11.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 272.65 |
| Forward PS | 789.56 |
| PB Ratio | 3.98 |
| P/TBV Ratio | 4.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 235.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.12, with a Debt / Equity ratio of 0.00.
| Current Ratio | 13.12 |
| Quick Ratio | 12.81 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -34.71% and return on invested capital (ROIC) is -24.49%.
| Return on Equity (ROE) | -34.71% |
| Return on Assets (ROA) | -23.37% |
| Return on Invested Capital (ROIC) | -24.49% |
| Return on Capital Employed (ROCE) | -42.46% |
| Revenue Per Employee | $62,231 |
| Profits Per Employee | -$1.47M |
| Employee Count | 78 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +29.39% in the last 52 weeks. The beta is 1.00, so DNTH's price volatility has been similar to the market average.
| Beta (5Y) | 1.00 |
| 52-Week Price Change | +29.39% |
| 50-Day Moving Average | 23.67 |
| 200-Day Moving Average | 21.56 |
| Relative Strength Index (RSI) | 83.36 |
| Average Volume (20 Days) | 996,509 |
Short Selling Information
The latest short interest is 5.58 million, so 14.43% of the outstanding shares have been sold short.
| Short Interest | 5.58M |
| Short Previous Month | 5.98M |
| Short % of Shares Out | 14.43% |
| Short % of Float | 49.21% |
| Short Ratio (days to cover) | 15.25 |
Income Statement
In the last 12 months, DNTH had revenue of $4.85 million and -$114.75 million in losses. Loss per share was -$3.25.
| Revenue | 4.85M |
| Gross Profit | 4.85M |
| Operating Income | -129.92M |
| Pretax Income | -56.68M |
| Net Income | -114.75M |
| EBITDA | -129.81M |
| EBIT | -129.92M |
| Loss Per Share | -$3.25 |
Full Income StatementBalance Sheet
The company has $257.39 million in cash and $1.33 million in debt, giving a net cash position of $307.76 million or $7.96 per share.
| Cash & Cash Equivalents | 257.39M |
| Total Debt | 1.33M |
| Net Cash | 307.76M |
| Net Cash Per Share | $7.96 |
| Equity (Book Value) | 303.08M |
| Book Value Per Share | 9.42 |
| Working Capital | 243.51M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$100.23 million and capital expenditures -$126,000, giving a free cash flow of -$100.36 million.
| Operating Cash Flow | -100.23M |
| Capital Expenditures | -126,000 |
| Free Cash Flow | -100.36M |
| FCF Per Share | -$2.59 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -2,676.56% |
| Pretax Margin | -2,364.11% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DNTH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -71.34% |
| Shareholder Yield | -71.34% |
| Earnings Yield | -7.92% |
| FCF Yield | -6.93% |
Analyst Forecast
The average price target for DNTH is $61.57, which is 64.32% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $61.57 |
| Price Target Difference | 64.32% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 100.14% |
| EPS Growth Forecast (5Y) | 9.58% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DNTH has an Altman Z-Score of 17.18 and a Piotroski F-Score of 1.
| Altman Z-Score | 17.18 |
| Piotroski F-Score | 1 |
